A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
|Articles|November 1, 1999
Supplements and Featured Publications
- The Clinical and Economic Impact of Pneumococcal Disease in the Pediatric Population
- Volume 5
- Issue 17 Suppl
The Clinical Impact of Pneumococcal Conjugate Vaccines
Author(s)Steven Black, MD
Advertisement
Articles in this issue
almost 27 years ago
Participating Facultyalmost 27 years ago
Introductionalmost 27 years ago
Epidemiology of Pneumococcal Diseasealmost 27 years ago
The Costs of Antimicrobial Treatment Failure in Acute Otitis Mediaalmost 27 years ago
Prevention of Pneumococcal Disease in High-Risk Pediatric Groupsalmost 27 years ago
Economic Impact of Pneumococcal Conjugate Vaccine in Managed Carealmost 27 years ago
Into the Era of the Pneumococcal Conjugate Vaccinealmost 27 years ago
Selected Abstractsalmost 27 years ago
CME Quizalmost 27 years ago
BibliographyAdvertisement
Related to this article
Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Preparing Practices for the Next Era of Hepatitis B Care
5